Ipamorelin alternatives.
10 compounds compared to Ipamorelin, ranked by published evidence tier and regulatory status, not by what's marketed hardest.
Ipamorelin is already the answer to a different alternatives search. It was characterized by Novo Nordisk researchers as the first GHRP-receptor agonist with selectivity for GH release approaching that of GHRH, which is why people move to it from the earlier GHRPs that also push cortisol, prolactin, or appetite. So anyone searching for an alternative to ipamorelin is usually after something the whole class lacks: approval. It is not approved by the FDA for any indication, was the subject of pharmacy-compounding review rather than drug approval, and is prohibited in sport by WADA at all times. Within the secretagogues, selectivity is the ceiling, not evidence.
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) belonging to the growth hormone-releasing peptide (GHRP) class, sometimes described as a "third-generation" GHRP.
- 01GHRP-1D tierResearch / preclinicalgrowth hormone-releasing peptide-1
Acts through the ghrelin-receptor agonism pathway, like Ipamorelin. Research / preclinical.
- 02GHRP-2D tierResearch / preclinical
Acts through the ghrelin-receptor agonism pathway, like Ipamorelin. Research / preclinical.
- 03GHRP-6D tierResearch / preclinical
Acts through the ghrelin-receptor agonism pathway, like Ipamorelin. Research / preclinical.
- 04HexarelinD tierResearch / preclinical
Acts through the ghrelin-receptor agonism pathway, like Ipamorelin. Research / preclinical.
- 05
- 06
- 07SermorelinC tierResearch / preclinical
Same category: growth hormone. Research / preclinical.
- 08
- 09CJC-1295F tierResearch / preclinical
Same category: growth hormone. Research / preclinical.
- 10IGF-1 LR3F tierResearch / preclinical
Same category: growth hormone. Research / preclinical.
An “alternative” here means a compound that shares Ipamorelin's mechanism pathway or sits in the same category, not a marketing substitute. Each is ordered by PepCue's evidence tier (a weighted 0–100 score across human data, safety, replication and regulatory clarity), then by whether it's actually approved. This is a research reference, not medical or purchasing advice: an alternative sitting higher on evidence does not mean it's right, safe, or legal for any given use. Reviewed June 1, 2026.
PepCue keeps every compound, dose and lab in one private, provider-ready timeline, whichever one you land on.